With Novartis, ImmunoGen Adds $45 Mil. And Another Licensor For Its Antibody-Drug Conjugate Platform

The deal gives Novartis access to develop therapeutics against an unspecified number of targets, while ImmunoGen gets more good news on top of positive Phase II data for its lead candidate.